SAA Consensus Statement EAS 2021: Triglyceride-rich lipoproteins and their remnant particles – a review of metabolism, role in atherosclerotic cardiovascular disease, and new therapeutic strategies

Ginsberg HN, Packard CJ, Chapman MJ et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42(47): 4791–4806. Dostupné z DOI: <http://doi: 10.1093/eurheartj/ehab551>.

Das Pradhan A, Glynn RJ, Fruchart JC et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387(21): 1923–34. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2210645>.

Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317(20): 1237–1245. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198711123172001>.

Rubins HB, Robins SJ, Collins D et al. [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group]. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341(6): 410–418. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199908053410604>.

Chait A, Eckel RH, Vrablik M et al. Lipid-lowering in diabetes: An update. Atheroscleros 2024; 394: 117313is. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2023.117313>.

Virani SS. The Fibrates Story – A Tepid End to a PROMINENT Drug. N Engl J Med 2022; 387(21): 1991–1992. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe2213208>.

Corpechot C, Chazouillères O, Rousseau A et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018; 378(23): 2171–2181. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1714519>.

Chew EY, Ambrosius WT, Davis MD et al. [ACCORD Study Group; ACCORD Eye Study Group]. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363(3): 233–44. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1001288>.

Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370(9600): 1687–1697. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)61607–9>.

Preiss D, Logue J, Sammons E et al. Effect of Fenofibrate on Progression of Diabetic Retinopathy. NEJM Evid 2024; 3(8): EVIDoa2400179. Dostupné z DOI: <http://dx.doi.org/10.1056/EVIDoa2400179>.